Background <p>C-reactive protein (CRP) is a risk factor for atherosclerosis. Although inflammation may confound this association, CRP itself has been hypothesized to possess both pro-atherosclerotic and pro-inflammatory properties. In this study, we aimed to elucidate the mechanism by which CRP may modulate bioactive lipid mediators.</p> Results <p>We found that the overexpression of human CRP increased plasma IL-6 and TNF-a levels in mice. Moreover, the conditioned medium of CRP-overexpressing HepG2 cells increased the release of these cytokines from RAW264.7 cells to a greater degree than recombinant CRP. Lipidomics analyses then revealed that the overexpression of CRP increased the total levels of plasma lysophosphatidic acid, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, and sphingosine 1-phosphate in mice. It also increased the levels of pro-inflammatory arachidonic acid derivatives, including PGE2 metabolites, LTA4 metabolites, and oxylipids, and decreased the levels of anti-inflammatory eicosapentaenoic acid- and docosahexaenoic acid-derived mediators. In regard to the mechanisms, analyses of CRP-overexpressing HepG2 cells suggested that CRP may increase the hepatic production of glycero-lysophospholipids, and may also modulate eicosanoids and related mediators outside the liver. Finally, analyses of the fraction separated using anti-CRP IgG suggested that CRP can bind several lipid mediators including sphingosine 1-phosphate, PGE2, and PGF2a.</p> Conclusions <p>CRP may modulate lysophospholipids, and eicosanoids, and related mediators in pro-atherosclerotic and pro-inflammatory directions.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

C-reactive protein modulates lipid mediators in a pro-inflammatory direction

  • Makoto Kurano,
  • Kazuhisa Tsukamoto,
  • Hideaki Isago,
  • Masumi Hara,
  • Yutaka Yatomi

摘要

Background

C-reactive protein (CRP) is a risk factor for atherosclerosis. Although inflammation may confound this association, CRP itself has been hypothesized to possess both pro-atherosclerotic and pro-inflammatory properties. In this study, we aimed to elucidate the mechanism by which CRP may modulate bioactive lipid mediators.

Results

We found that the overexpression of human CRP increased plasma IL-6 and TNF-a levels in mice. Moreover, the conditioned medium of CRP-overexpressing HepG2 cells increased the release of these cytokines from RAW264.7 cells to a greater degree than recombinant CRP. Lipidomics analyses then revealed that the overexpression of CRP increased the total levels of plasma lysophosphatidic acid, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, and sphingosine 1-phosphate in mice. It also increased the levels of pro-inflammatory arachidonic acid derivatives, including PGE2 metabolites, LTA4 metabolites, and oxylipids, and decreased the levels of anti-inflammatory eicosapentaenoic acid- and docosahexaenoic acid-derived mediators. In regard to the mechanisms, analyses of CRP-overexpressing HepG2 cells suggested that CRP may increase the hepatic production of glycero-lysophospholipids, and may also modulate eicosanoids and related mediators outside the liver. Finally, analyses of the fraction separated using anti-CRP IgG suggested that CRP can bind several lipid mediators including sphingosine 1-phosphate, PGE2, and PGF2a.

Conclusions

CRP may modulate lysophospholipids, and eicosanoids, and related mediators in pro-atherosclerotic and pro-inflammatory directions.